4
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Patent Update: Cardiovascular & Renal: Endothelin receptor antagonists

Pages 1361-1365 | Published online: 03 Mar 2008
 

Abstract

Data from animal models indicate that endothelin (ET) receptor antagonists may have therapeutic utility in hypertension, myocardial infarction and subsequent reperfusion injury, acute renal failure and asthma. Selective antagonists for the two receptor subtypes (ETa and ETb) are now available. Nonpeptide ETA-selective antagonists are now available and have the potential of developing into orally active agents in clinical studies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.